2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4202 Factors associated with graft Failure–Related mortality after HLA-mismatched allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis

Amna Bint I Munir, MBBS, Nabeeha Noor2, Muhammad Kashif Amin, MD, MSc, FACP3, Muhammad Shahzad Sarwar, N/A4, Shah Rukh5, Mehdi Hamadani, MD6, Abhinav Vyas, MD7, Michael Jaglal, MD8, Joseph P McGuirk, DO9, Moazzam Shahzad, MD10, Muhammad Umair Mushtaq, MD11
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
10 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

HLA-mismatched allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCy) has expanded donor access using both haploidentical (haplo) and mismatched unrelated donors (MMUD). Graft failure remains a clinical concern, yet contemporary rates of graft failure–related mortality (GFRM) in the PTCy era are not well defined. We aimed to quantify the incidence and timing of GFRM and to explore associated patient and transplant factors in a large Center for International Blood and Marrow Transplant Research (CIBMTR) cohort.

Methods:

We included adult (≥18 years) recipients of a first HLA-mismatched allo-HCT (haplo or MMUD) with PTCy-based GVHD prophylaxis reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2013 and 2021. GFRM was defined as death with graft rejection/failure coded as the primary cause of death. The primary endpoint was the cumulative incidence of GFRM, estimated by cumulative incidence functions with death from other causes as the competing event. Exploratory associations were evaluated using a pre-specified, parsimonious cause-specific Cox model that included donor type, recipient age, HCT-CI, graft source, and conditioning intensity; no data-driven variable selection was performed. Pre-specified sensitivity analyses included Fine-Gray subdistribution models, ridge-penalized Cox regression, and stratification by calendar era (2013–2016 vs 2017–2021). Multivariable analyses were complete-case (6,417/6,523; 98.4%). Risk-factor findings are considered exploratory and hypothesis-generating given the limited number of events.

Results:

A total of 6,523 adults were included (haplo 5,493 [84.2%]; MMUD 1,030 [15.8%]), among whom 2,955 deaths (45.3%) occurred. GFRM was rare, occurring in only 53 patients (0.8% of the cohort; 1.8% of all deaths), including 41 of 5,493 haplo recipients (0.7%) and 12 of 1,030 MMUD recipients (1.2%). Events occurred early (median 2.5 months, IQR 1.8–3.9), with 34 of 53 events (64%) by day 100 and 47 of 53 (89%) within 6 months. The cumulative incidence of GFRM was 0.7% (95% CI 0.5–1.0) at 6 months and 0.8% (0.6–1.1) at both 12 and 24 months. By donor type, 24-month cumulative incidence was 0.8% (0.6–1.0) for haplo and 1.1% (0.6–1.9) for MMUD recipients. GFRM remained uncommon across calendar eras (0.6% in 2013–2016 and 0.9% in 2017–2021). In exploratory multivariable models, higher comorbidity burden (HCT-CI ≥3) was associated with increased risk of GFRM (HR 1.95, 95% CI 1.11–3.44; P=0.02). Donor type was not significantly associated (MMUD vs haplo HR 1.47, 95% CI 0.77–2.80; P=0.24); the analysis was underpowered to exclude a clinically meaningful difference. Recipient age (per 10 years: HR 1.14, 95% CI 0.91–1.42), graft source (PBSC vs marrow: HR 0.78, 95% CI 0.42–1.47), and conditioning intensity (MAC vs RIC/NMA: HR 1.04, 95% CI 0.55–1.99) showed no significant associations. Fine-Gray models yielded concordant estimates (HCT-CI ≥3 sHR 1.87, 95% CI 1.07–3.27; MMUD sHR 1.51, 95% CI 0.79–2.89). Ridge-penalized Cox models attenuated all hazard ratios toward the null.

Conclusions:

Graft failure–related mortality after HLA-mismatched allo-HCT with PTCy is uncommon (~0.8%), occurs mainly within the first 6 months, and accounts for <2% of deaths. Higher HCT-CI showed an exploratory association, but findings are limited by sparse events and missing biologic variables. These data provide contemporary benchmarks for this rare outcome.

Amna Bint I Munir, MBBS: No relevant conflicts of interest to declare.